Ianalumab, an experimental treatment for Sjögren’s disease from Novartis, has been granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA). The FDA gives this designation to experimental therapies that have the potential to address unmet needs in the care of serious diseases, with the goal…